Company intelligence / Profile preview

Guangzhou Xiling Biotechnology

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Guangzhou Xiling Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the development of innovative cell therapies for oncology. Established in 2021, the company focuses on allogeneic natural killer (NK) cell products, leveraging a proprietary platform to create off-the-shelf treatments for advanced cancers. Its lead program, CEL001, is a non-genetically modified allogeneic NK cell therapy that received IND approval from the CDE in 2024 and entered Phase 1 clinical trials for advanced malignant solid tumors in 2025. The company also collaborates with partners like Beijing Jingda Biotechnology on additional pipeline candidates such as JD012-CEL.

Therapeutic areas: Oncology
Modalities: Cell therapyNK cell therapy
Industry: Biotech

Partnerships

Beijing Jingda BiotechnologyBeijing Tongli Haiyuan Biological

Beyond the preview

Go deeper on Guangzhou Xiling Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Xiling Biotechnology.

Explore the full profile